Microvesicles and Microvesicle-Associated microRNAs Reflect Glioblastoma Regression: Microvesicle-Associated miR-625-5p Has Biomarker Potential

Abstract

Glioblastoma (GB) is the most aggressive and recurrent form of brain cancer in adults. We hypothesized that the identification of biomarkers such as certain microRNAs (miRNAs) and the circulating microvesicles (MVs) that transport them could be key to establishing GB progression, recurrence and therapeutic response. For this purpose, circulating MVs were isolated from the plasma of GB patients (before and after surgery) and of healthy subjects and characterized by flow cytometry. OpenArray profiling and the individual quantification of selected miRNAs in plasma and MVs was performed, followed by target genes’ prediction and in silico survival analysis. It was found that MVs’ parameters (number, EGFRvIII and EpCAM) decreased after the surgical resection of GB tumors, but the inter-patient variability was high. The expression of miR-106b-5p, miR-486-3p, miR-766-3p and miR-30d-5p in GB patients’ MVs was restored to control-like levels after surgery: miR-106b-5p, miR-486-3p and miR-766-3p were upregulated, while miR-30d-5p levels were downregulated after surgical resection. MiR-625-5p was only identified in MVs isolated from GB patients before surgery and was not detected in plasma. Target prediction and pathway analysis showed that the selected miRNAs regulate genes involved in cancer pathways, including glioma. In conclusion, miR-625-5p shows potential as a biomarker for GB regression or recurrence, but further in-depth studies are needed.

The role of CEMIP in cancers and its transcriptional and post-transcriptional regulation

“…MiR-486-3p displays tumor-suppressive characteristics, being downregulated in hepatocellular carcinoma (HCC) ( Ji et al, 2020 ), retinoblastoma ( Yang et al, 2020 ), osteosarcoma ( Zhang et al, 2021 ), cervical cancer ( Ye et al, 2016 ), adrenocortical carcinoma ( Li et al, 2021a ) ,and oral squamous cell carcinoma ( Garajei et al, 2022 ). However, in glioblastoma ( Simionescu et al, 2022 ), non-small cell lung cancer ( Jin et al, 2022 ), and β-thalassemia ( Lulli et al, 2013 ), it demonstrates an upregulation, thereby fostering disease progression.…”

Extracellular vesicles for diagnosis and therapy of gliomas: problems and opportunities

“…В современных исследованиях показано, что прогностическими и диагностическими маркерами глиом, транспортируемыми ВВ, могут служить различные биологические молекулы. Однако наиболее многообещающими биомаркерами являются миРНК, которые могут быть ассоциированы с процессами индукции глиобластомы [24,25,32,33]. Так, в исследовании [25] с помощью панели "TaqMan OpenArray Human Advanced MicroRNA" Simionescu и соавт.…”

“…Однако наиболее многообещающими биомаркерами являются миРНК, которые могут быть ассоциированы с процессами индукции глиобластомы [24,25,32,33]. Так, в исследовании [25] с помощью панели "TaqMan OpenArray Human Advanced MicroRNA" Simionescu и соавт. проводили определение профиля экспрессии миРНК в ВВ, выделенных из плазмы крови пациентов с глиобластомой и у здоровых людей.…”

Microvesicle-associated and circulating microRNAs in diabetic dyslipidemia: miR-218, miR-132, miR-143, and miR-21, miR-122, miR-155 have biomarker potential

“…The miRNAs are known as small non-coding RNAs which regulate gene expression post-transcriptionally through the inhibition of translation and/or the degradation of messenger RNA (mRNA) and they have been found in several body fluids, including blood, circulating EVs or associated with lipoproteins or protein complexes [ 17 , 18 ]. The levels of miRNAs are modified during disease progression and miRNAs’ circulating profiles often reflect their modified expression in the tissue of origin or indicate increased intercellular communication [ 19 ]. There are clear data on a possible use of miRNAs as diagnostic biomarkers and therapeutic targets for the endothelial dysfunction in hypertensive patients [ 20 ].…”